Precigen, Inc.

Businessfiled

Precigen, Inc. operates in Pharmaceuticals, based in GERMANTOWN. Precigen is a commercial-stage biopharmaceutical company focused on urgently delivering highly targeted precision medicines to address difficult-to-treat diseases with high unmet patient need.

Sub-sector tags: ai/ml, healthtech.

Capital & rounds (filed)filed

Precigen, Inc. has raised $624M in disclosed capital across 18 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $150M on 2013-03-01.

Most recent recorded round closed around 2020-12-02.

Valuation (modeled)modeled

Provath models Precigen, Inc. at approximately $405M (range $62M–$846M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.11× the median modeled value of Series D+ Pharmaceuticals companies in 2019–2021 (15 peers) — value vs value, same stage and era. Issuer reports $25M–$100M revenue while modeled below niche peers.

Financing rhythm & timingmixed

Historic cadence: a new round about every 6 months.

Last raise 5.6 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.7× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 100% of Pharmaceuticals peers (1610 compared).

Modeled value ranks above 79% of those peers.

Closest niche peers: Nuvation Bio Inc., Recursion Pharmaceuticals, Inc., Vyripharm Enterprises, Inc., Verona Pharma plc, Cingulate Inc..

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.